WebApr 11, 2024 · The 15 analysts offering price forecasts for Recursion Pharmaceuticals, have a median target of 19.93, with a high estimate of 37.00 and a low estimate of 7.00. The median estimate represents a... WebMar 17, 2024 · Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.57% and 37.04%, respectively, for the quarter ended June 2024. Do the numbers hold …
Recursion (@RecursionPharma) Twitter
WebRecursion Pharmaceuticals started at buy with $31 stock price target at BofA Securities May. 11, 2024 at 9:44 a.m. ET by Tomi Kilgore Recursion Pharmaceuticals started at … WebJul 13, 2024 · SALT LAKE CITY, July 13, 2024 - Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Board (TAB), chaired by Joseph Miletich, MD, PhD. … gst 104 use of library material
RXRX Recursion Pharmaceuticals Inc. Stock Price & News - WSJ
WebMar 28, 2024 · Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion OS, a platform built … WebApr 5, 2024 · The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Thursday, March 16, 2024. The analyst firm set a price target for 17.00 expecting RXRX to rise to ... WebApr 10, 2024 · SVB Securities analyst Mani Foroohar reiterated a Hold rating on Recursion Pharmaceuticals (RXRX - Research Report) on February 27 and set a price target of $9.00. … financial annual turnover meaning